Medicines not recommended for inclusion in the who essential medicines list: a retrospective observational study
Enrico Costa(Brigham and Women's Hospital), Lorenzo Moja(World Health Organization), Veronika J. Wirtz(Boston University), Hubert G. M. Leufkens(Utrecht University), Benedikt Huttner(World Health Organization), Francesco Nonino(Istituto delle Scienze Neurologiche di Bologna), Nicola Magrini(Evidence (Italy)), Bernadette Cappello(World Health Organization), Hendrika A. van den Ham(Utrecht University), Vittorio Del Grosso(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Armando A. Genazzani(University of Turin)
Cited by 2
Related Papers
Timing Matters in Hip Fracture Surgery: Patients Operated within 48 Hours Have Better Outcomes. A Meta-Analysis and Meta-Regression of over 190,000 Patients
|PLoS ONE|2012|631
The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance
|The Lancet Infectious Diseases|2025|526
The <i>WHO AWaRe (Access, Watch, Reserve) antibiotic book</i> and prevention of antimicrobial resistance
|Bulletin of the World Health Organization|2023|276
WHO global research priorities for antimicrobial resistance in human health
|The Lancet Microbe|2024|183
Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey
|The Lancet Oncology|2021|170